Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study

    September 2024 in “ Cardiovascular Drugs and Therapy ”
    Michael Nakhla, Ambica Nair, Prachi Balani, Aditi Ujjawal, Pramukh Arun Kumar, Mahati Dasari, Zeynep Yukselen, Kannu Bansal, Sarju Ganatra, Sourbha S. Dani
    TLDR GLP1-RAs may have higher reports of suicidal events and hair loss compared to other diabetes drugs.
    A real-world pharmacovigilance study analyzed data from four databases to assess the safety of GLP1-RAs concerning suicide, hair loss, and aspiration risks. The study found no significant association between GLP1-RAs and these adverse events. However, GLP1-RAs, especially semaglutide and liraglutide, had higher reporting rates for suicidal events compared to other antidiabetic drugs like DPP4is and SGLT2is. They were also the most reported class for hair loss, with semaglutide, liraglutide, and dulaglutide being prominent. Aspiration events were less associated with GLP1-RAs, with sitagliptin and DPP4is having higher reports. The study emphasizes the need for ongoing monitoring and reporting of these adverse events.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results